Ziftomenib (in combination with SoC cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza))- (KOMET-007)

Aug. 10, 2026: Kura Oncology (NASDAQ: KURA) announced a Blood publication detailing the discovery and preclinical characterization of ziftomenib, a menin inhibitor approved by the FDA in 2025 for adults with relapsed/refractory NPM1-mutated AML.

The paper reports potent, selective inhibition of the menin-KMT2A interaction and activity across KMT2A-rearranged, NPM1-mutated, and NUP98-rearranged leukemia models. In preclinical studies, ziftomenib suppressed key KMT2A-regulated genes including MEIS1 and HOXA9, induced differentiation, reduced leukemia cell viability, drove leukemia regression, and extended survival in multiple xenograft and patient-derived xenograft models; durable responses were seen after treatment discontinuation in one patient-derived model.

The publication also describes activity against certain treatment-emergent MEN1 resistance mutations associated with other menin inhibitors, supporting a differentiated binding profile. The release cites clinical data from KOMET-001 showing MEN1-M327I emerged in 1 of 29 evaluable patients.

Kura said ziftomenib is being studied in combination across the AML treatment continuum, including newly diagnosed and relapsed/refractory NPM1-mutated AML, KMT2A-rearranged AML, and FLT3-mutated AML, and is also being explored in advanced gastrointestinal stromal tumors.